dr. woyach on ibrutinib regimens in frontline cll
Published 4 years ago • 152 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
1:46
dr. woyach on frontline treatment options in cll
-
1:21
dr. woyach on clinical trials examining novel triplets in cll
-
1:47
dr. woyach on ibrutinib resistance in cll
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
1:16
dr. woyach on ibrutinib and peripheral lymphocytosis in patients with chronic lymphocytic leukemia
-
1:39
dr. woyach on the role of acalabrutinib in cll
-
1:17
dr. woyach on treatment challenges in cll
-
1:53
dr. woyach on using ibrutinib in combination therapies
-
1:33
dr. woyach on ongoing research with btk inhibitors in cll
-
1:25
dr. woyach on the role of chemoimmunotherapy in cll
-
6:03
ibrutinib’s role as frontline therapy in cll
-
1:26
dr. woyach discusses peripheral lymphocytosis in patients with cll taking ibrutinib
-
1:00
dr. smith on ibrutinib-based therapies in cll
-
1:17
dr. susan o'brien compares ibrutinib and chemoimmunotherapy in frontline cll
-
1:17
dr. woyach discusses progression on ibrutinib with the acquisition of resistance mutations
-
5:52
ibrutinib vs. chemoimmunotherapy for chronic lymphocytic leukemia (cll) treatment - ash 2021
-
1:28
dr. woyach on remaining sequencing questions in cll
-
1:08
dr. woyach on the role of small molecule inhibitors in cll
-
9:15
obinutuzumab venetoclax for frontline cll